KYTHERA Announces Positive Interim Results from Open-Label Study of ATX-101 in Reduction of 'Double Chin'

KYTHERA Announces Positive Interim Results from Open-Label Study of ATX-101 in Reduction of 'Double Chin'

By: Latest Articles from Benzinga.com

Posted on March 02, 2013 at 10:46 AM EST

KYTHERA Biopharmaceuticals (NASDAQ: KYTH ) today announced positive interim results from a Phase IIIb, multi-center, open-label study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational

Related Stocks:

KYTHERA BIOPHRM NewStar Financial, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates